Citi: Tigermed (03347.HK) regulatory uncertainty removed, reiterates "Buy" rating and top pick status

Zhito Finance APP has learned that Citi released a research report stating that last Friday (the 11th), Tigermed (03347.HK) announced the results of the China Securities Regulatory Commission's investigation into Tigermed co-founders Ye Xiaoping and Cao Xiaochun, in which the Zhejiang Regulatory Bureau intends to issue a warning to Ye Xiaoping and Cao Xiaochun and impose a fine of RMB 500,000 on each. The investigation involved suspected violations of information disclosure obligations by the two in changes in their shareholdings in the company. Citi believes the outcome is consistent with its previous estimate and removes regulatory uncertainty. Citi maintains a positive view on Tigermed's order growth and earnings visibility, and reiterates its "Buy" rating and top pick status. Tigermed's A-share target price is RMB 67, and its H-share target price is HKD 73.